Table 1.
Pre- and postoperative hormonal data of overall acromegalic patients (n = 40) during longitudinal follow-up; postglucose GH nadir levels are additionally categorized by sex and tumor size. Mean ± SD values are shown.
| Parameter | Preoperative | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Mean (years) | — | 0.7 ± 0.4 | 6.9 ± 5.4 | 17.2 ± 8.4 |
| Age (years) | 40.4 ± 12.3 | 45.1 ± 11.3 | 50.7 ± 11.0 | 55.4 ± 11.3 |
| IGF-I (SDS) | 9.6 ± 5.2 | 0.6 ± 1.9 | −0.32 ± 0.9 | −0.28 ± 1.1■ |
| Basal GH (μg/L) | 19.9 ± 20.4 | 1.1 ± 0.9 | 1.0 ± 1.4 | 0.9 ± 1.2 |
| Range | (1.0–73.0) | (0.0–3.0) | (0.0–7.0) | (0.0–4.4) |
| Nadir GH (μg/L) | 16.0 ± 21.9 | 0.39 ± 0.38 | 0.27 ± 0.29 | 0.22 ± 0.20■ |
| Female (n = 25) | 19.6 ± 27.7 | 0.45 ± 0.42 | 0.27 ± 0.25 | 0.24 ± 0.21■ |
| Male (n = 15) | 11.2 ± 9.5 | 0.30 ± 0.30 | 0.29 ± 0.37 | 0.21 ± 0.19 |
| Micro (n = 15) | 7.2 ± 6.0 | 0.27 ± 0.29 | 0.22 ± 0.27 | 0.18 ± 0.18 |
| Macro (n = 25) | 27.0 ± 28.5a | 0.51 ± 0.42 | 0.31 ± 0.31 | 0.25 ± 0.21■ |
Phase 1: at the time of remission.
Phase 2: at the time of the last available assessment with the GH assay standardized to IS 80/505.
Phase 3: after a long-term follow-up with ultrasensitive GH assay standardized to IS 98/574.
Micro: microadenoma; macro: macroadenoma.
■ P < 0.05 versus phase 1.
a P < 0.05 versus microadenoma.